Table 1 Baseline characteristics of patients diagnosed with primary invasive breast cancer (n = 30,060), from 2004 to 2018 in Norway.
No BB use (N = 25,599) | Non-selective BB (N = 577) | Selective BB (N = 3884) | |
|---|---|---|---|
Age (years) | |||
Median [q1, q3] | 62 [56, 69] | 67 [61, 75] | 69 [63, 78] |
Attained education | |||
Primary | 6188 (24.2) | 179 (31.0) | 1416 (36.5) |
Secondary | 12,220 (47.7) | 296 (51.3) | 1863 (48.0) |
Higher | 7009 (27.4) | 97 (16.8) | 587 (15.1) |
Missing | 182 (0.7) | 5 (0.9) | 18 (0.5) |
Marital status | |||
Not married/not in partnership | 10,818 (42.3) | 278 (48.2) | 1841 (47.4) |
Married/in partnership | 14,720 (57.5) | 299 (51.8) | 2036 (52.4) |
Missing | 61 (0.2) | 0 (0.0) | 7 (0.2) |
Children | |||
0 | 3020 (11.8) | 67 (11.6) | 404 (10.4) |
1 | 3694 (14.4) | 77 (13.3) | 514 (13.2) |
2 | 10,449 (40.8) | 226 (39.2) | 1472 (37.9) |
≥3 | 8436 (33.0) | 207 (35.9) | 1494 (38.5) |
Country of origin | |||
Norway | 23,282 (90.9) | 536 (92.9) | 3618 (93.2) |
Another Nordic countrya | 742 (2.9) | 17 (2.9) | 91 (2.3) |
Rest of the world | 1575 (6.2) | 24 (4.2) | 175 (4.5) |
Stage | |||
Localised | 15,578 (60.9) | 342 (59.3) | 2145 (55.2) |
Regional | 7609 (29.7) | 167 (28.9) | 1206 (31.1) |
Distant | 908 (3.5) | 29 (5.0) | 185 (4.8) |
Missing | 1504 (5.9) | 39 (6.8) | 348 (9.0) |
T-descriptor (dimension) | |||
1 | 15,249 (59.6) | 300 (52.0) | 1954 (50.3) |
2 | 6243 (24.4) | 170 (29.5) | 1049 (27.0) |
3 | 797 (3.1) | 20 (3.5) | 138 (3.6) |
4 | 502 (2.0) | 11 (1.9) | 104 (2.7) |
Missing | 2808 (11.0) | 76 (13.2) | 639 (16.5) |
N-descriptor (lymph nodal involvement) | |||
0 | 15,961 (62.4) | 352 (61.0) | 2178 (56.1) |
1 | 6291 (24.6) | 132 (22.9) | 945 (24.3) |
2 | 746 (2.9) | 25 (4.3) | 129 (3.3) |
3 | 424 (1.7) | 11 (1.9) | 71 (1.8) |
Missing | 2177 (8.5) | 57 (9.9) | 561 (14.4) |
Histology | |||
Ductal Carcinoma | 20,170 (78.8) | 456 (79.0) | 3007 (77.4) |
Lobular Carcinoma | 3284 (12.8) | 87 (15.1) | 468 (12.0) |
Other carcinoma | 2145 (8.4) | 34 (5.9) | 409 (10.5) |
Tumour grade | |||
I | 5737 (22.4) | 122 (21.1) | 784 (20.2) |
II | 11,736 (45.8) | 276 (47.8) | 1747 (45.0) |
III | 5962 (23.3) | 125 (21.7) | 890 (22.9) |
Missing | 2164 (8.5) | 54 (9.4) | 463 (11.9) |
Ki-67 | |||
Median [q1, q3] | 21 [12, 37] | 23 [12, 36] | 24 [14, 39] |
Missing | 12,522 (48.9) | 346 (60.0) | 2020 (52.0) |
Molecular subtype | |||
Luminal A | 5612 (21.9) | 119 (20.6) | 736 (18.9) |
Luminal B HER2 negative | 10,780 (42.1) | 252 (43.7) | 1637 (42.1) |
Luminal B HER2 positive | 2000 (7.8) | 45 (7.8) | 272 (7.0) |
HER2 positive | 940 (3.7) | 12 (2.1) | 134 (3.5) |
Triple-negative | 1775 (6.9) | 31 (5.4) | 281 (7.2) |
Missing | 4492 (17.5) | 118 (20.5) | 824 (21.2) |
Concomitant medication use | |||
Angiotensin-converting enzyme inhibitorsb | 981 (3.8) | 65 (11.3) | 627 (16.1) |
Angiotensin receptor blockersb | 3779 (14.8) | 191 (33.1) | 1389 (35.8) |
Calcium channel blockersb | 1959 (7.7) | 121 (21.0) | 970 (25.0) |
Diureticsb | 3406 (13.3) | 226 (39.2) | 1741 (44.8) |
Low dose aspirin | 2254 (8.8) | 147 (25.5) | 1368 (35.2) |
COX2 inhibitors | 876 (3.4) | 11 (1.9) | 75 (1.9) |
Statins | 3720 (14.5) | 194 (33.6) | 1711 (44.1) |
Antidiabetics | 1028 (4.0) | 71 (12.3) | 458 (11.8) |
Follow-up time (years) | |||
Median [q1, q3] | 5.2 [2.3, 9.1] | 5.7 [2.9, 9.6] | 4.4 [1.9, 8] |
